Ozempic in the Czech Republic: Why It's a Diabetes Medicine – and What That Means for Weight Loss
Medically reviewed by MUDr. Iveta Novotná, obesitologist
Ozempic in the Czech Republic is authorised only for type 2 diabetes. How the Czech eRecept rules changed since 2023, what applies now and what it means for expats.

If you live in Czechia and have searched anything about weight loss lately, one brand name has almost certainly come up, and it is the one most surrounded by misunderstanding. The medicine behind it is not a weight-loss product, and the Czech eRecept system has applied special rules to it since 2023. Here is what it is approved for, what the e-prescription system actually allows, and what that means if you are dealing with obesity here.
What Ozempic is approved for in the EU
Ozempic contains semaglutide, a GLP-1 receptor agonist, given as a once-weekly injection from a pre-filled pen. The European Medicines Agency authorised it for a single purpose: the treatment of adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise, either alone when metformin is unsuitable or added to other diabetes medicines (EMA: Ozempic).
Weight management is not among its authorised indications. In the diabetes trials assessed by the regulator, treatment with Ozempic was associated with a beneficial fall in body weight (EMA: Ozempic), which is how the brand became attached to weight loss in public conversation. But a weight effect observed during treatment of a different condition is not an approved obesity treatment. In Czechia that distinction is not only legal and clinical, it has also been built into the eRecept system, as the next section explains.
Czech e-prescription rules: what has changed since 2023
Czechia built special prescribing rules for Ozempic into the national eRecept system in 2023 and has changed them twice since, so what applies today depends on the pack.
From 7 April 2023 the system rejected an Ozempic prescription unless it met all of these conditions (ePreskripce, 6 April 2023, in Czech):
- the prescription carried a diagnosis of diabetes mellitus (type 1 or type 2);
- the prescriber held a specialisation in internal medicine, diabetology or endocrinology;
- the quantity dispensed did not exceed 12 mg of active substance per 12 weeks;
- the payment type "patient pays" could not be selected, so the prescription had to run through health insurance.
From 1 November 2023 only the diagnosis requirement remained, and ePreskripce cancelled the other conditions (ePreskripce, 26 October 2023, in Czech). From 7 November 2025 it also cancelled all restrictions for one pack, the 0.5 mg pen with SÚKL code 0223053. For the 0.25 mg pack (code 0223052) and the 1 mg pack (code 0223055), a recorded diagnosis of type 1 or type 2 diabetes is still required when the prescription is issued (ePreskripce, 5 November 2025, in Czech).
SÚKL's database records that marketing of code 0223053 ended from 1 December 2025 for manufacturing reasons, with the registration still valid (SÚKL: 0223053). It was replaced by code 0272401, also a 0.5 mg pen, which SÚKL records as placed on the market from 8 October 2025 (SÚKL: 0272401). The ePreskripce notices do not mention the newer 0.5 mg code or the 2 mg pack (0255430). Your doctor or pharmacist can confirm which conditions apply to a specific pack (status as of 18 October 2026).
None of these technical rules changes what Ozempic is authorised for: it is registered only for type 2 diabetes, and weight loss is not an authorised use. Obesity is treated with products that carry an obesity indication, and only if a doctor judges treatment appropriate.
What expats ask most
These are practical questions foreign residents ask about Ozempic in Czechia, answered from official sources where they exist. Ozempic is authorised only for type 2 diabetes, and whether any treatment is appropriate is a doctor's decision.
Do I need a Czech GP to be prescribed Ozempic?
The condition the eRecept system sets is a diagnosis, not a GP registration: for the 0.25 mg and 1 mg packs, ePreskripce still requires a recorded type 1 or type 2 diabetes diagnosis on the prescription (ePreskripce, 5 November 2025, in Czech). If you are asking because of your weight, Ozempic is not the route, and a GP is not a prerequisite for an obesity assessment either; see obesity treatment in Czechia without a GP.
Do Czech pharmacies stock Ozempic?
Nationally, yes. SÚKL's database, consulted on 18 October 2026, marks the 0.25 mg, 0.5 mg (code 0272401), 1 mg and 2 mg packs as having an active presence on the Czech market, based on distributors' delivery reports for the previous three months (0.25 mg, 0.5 mg, 1 mg, 2 mg). That is the national picture, not the shelf of your pharmacy. Prescribed packs that one pharmacy has not dispensed can be collected at any other pharmacy, and you keep the original prescription code (ePreskripce, in Czech), so ask yours to check or order the pack, or try another. An eRecept is valid for 14 days by default unless the prescriber sets another period (ePreskripce, in Czech). More in GLP-1 availability in Czech pharmacies.
Can I use a prescription from another EU country, the UK or the US?
From another EU country, sometimes. Czech law accepts a prescription issued in an EU member state (§ 81g(2) of the Medicines Act, in Czech), but electronic prescriptions travel through a cross-border system that pharmacies join voluntarily. As of 18 October 2026, ePreskripce lists ten countries whose e-prescriptions can be collected in Czechia: Austria, Cyprus, Estonia, Finland, Greece, Latvia, Lithuania, Poland, Portugal and Spain (country table, in Czech). Its list of pharmacies ready to dispense them has more than 700 entries (pharmacy list, in Czech), so phone the pharmacy first. The EU rule behind this and what the pharmacist asks for are explained in Mounjaro in Czechia.
From the UK or the US the answer is different. On a plain reading of § 81g(2), a Czech pharmacy cannot dispense on such a prescription: neither country is an EU member state or in that table, and the Act's list names no prescription from outside the EU. See continuing GLP-1 treatment after moving to Czechia.
Can I bring my own pens from abroad?
Carrying pens for your own treatment is not the same as having them posted. Czech Customs says that medicines sold outside the EU may be brought in only in the quantity a traveller personally needs for the length of the trip in Czechia or the EU, such as a holiday or a visit (Czech Customs Administration, in Czech). That page gives no number of pens or weeks and does not mention moving here. It also does not cover pens bought in another EU country. Ask Customs or SÚKL before relying on a supply. Mail-order dispensing covers only medicines that are not tied to a prescription (SÚKL, in Czech), and SÚKL says Ozempic is legally available only through dispensing at a pharmacy, and that quality, safety and efficacy are not assured for packs from other sources (SÚKL, in Czech). The counterfeits section below covers the risk.
Can I be treated in English?
That depends on the doctor, because the language of a consultation is the provider's choice, so ask before you book. Ozempic is authorised only for type 2 diabetes, and a doctor decides whether any treatment is appropriate and may decline. EMA publishes the product information for Ozempic, including the package leaflet, in English, Czech and other European languages (EMA).
What does it cost?
This page quotes no prices, because pharmacy prices depend on the pack and change over time, and consultation fees are separate. For what treatment for obesity costs in Czechia, see what weight-loss treatment costs in Czechia.
Why demand for weight loss caused shortages
The 2023 restriction did not appear out of nowhere. In spring 2023 the manufacturer failed to deliver planned volumes to the Czech Republic, citing production capacity and sharply increased EU-wide demand. eRecept data showed a rising trend of prescriptions issued in self-pay mode, and the Ministry of Health instructed SÚKL to limit prescribing to the three specialisations listed in the rules section above, so that constrained supply reached the patients the medicine is approved and reimbursed for (Ministry of Health, April 2023, in Czech). Further interruptions to some strengths followed in July 2024 (manufacturer letter published by SÚKL, in Czech, PDF). Supply across the GLP-1 class has fluctuated since, so availability is worth checking: see GLP-1 availability in Czech pharmacies.
Counterfeits: why "no prescription" offers are a red flag
SÚKL has warned about a growing number of suspected counterfeit Ozempic pens circulating in the EU, affecting the 0.25 mg, 0.5 mg and 1 mg presentations. The regulator reports no information about counterfeit packs in the Czech legal distribution chain, and stresses that the medicine can be obtained legally only by dispensing at a pharmacy (SÚKL warning, in Czech). A counterfeit seized in Austria contained insulin instead of semaglutide; people who injected it had seizures and severe hypoglycaemia (ČT24, in Czech).
The rule of thumb is simple. In Czechia the only lawful path to any prescription medicine runs through a prescription and dispensing at a pharmacy counter. Mail-order supply of prescription medicines is illegal here: under § 85(1) of Act No. 378/2007 Coll. on Pharmaceuticals, only registered medicines whose dispensing is not tied to a prescription may be sent by post (SÚKL questions and answers, in Czech). So any site promising to post one to your address in Prague or elsewhere is outside the law, and what arrives is unverifiable. The warning signs are in illegal online pharmacies in Czechia.
How treatment for obesity is actually accessed here
If your concern is obesity rather than diabetes, the first step is not hunting for a particular product but a proper medical assessment. A doctor reviews your BMI, medical history, other medicines you take and your goals, then decides whether pharmacological treatment is appropriate at all. That assessment is not a formality: the doctor may conclude it is not suitable and decline it. Our BMI calculator gives you a starting point, but a calculator decides nothing.
Not having a registered GP is not an obstacle. Of the 554,000 people in Czechia without a registered GP, 65% are foreign nationals – roughly 360,000 people (expats.cz), and this care pathway does not require one, as we explain in obesity treatment in Czechia without a GP. At GoOn you complete an online questionnaire, then speak to a licensed Czech doctor by video in English, with no surcharge for the language. If the doctor concludes treatment is appropriate, they issue a standard Czech eRecept, which you collect at any pharmacy in the country; nothing is posted to you. Check with a doctor online whether treatment is suitable for you. You pay only for the consultations, and the medicine is paid separately at the pharmacy – see what weight-loss treatment costs in Czechia.
Which medicines do carry an obesity indication
At class level, the EU has authorised products specifically for weight management in adults meeting defined BMI criteria: semaglutide at a higher weekly dose (EMA: Wegovy) and tirzepatide (EMA: Mounjaro). They differ in dosing, evidence base and safety profile, and no product is right in the abstract.
This is where the dose distinction becomes concrete: the weight-management evidence for semaglutide comes from a higher weekly dose than the diabetes product provides. In the STEP 1 trial, participants with overweight or obesity and without type 2 diabetes taking semaglutide 2.4 mg lost on average 14.9% of body weight over 68 weeks, against 2.4% on placebo, with both groups also changing diet and physical activity (NEJM). A trial average is not a personal forecast; individual response varies widely, and some people respond weakly or stop early. A balanced comparison of the class, limitations included, is in GLP-1 medicines compared.
Side effects and contraindications
The most common adverse effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal pain, most pronounced at the start and when the dose is increased. Less common but serious events include pancreatitis and gallbladder problems, and the medicine is not intended for use in pregnancy or breastfeeding (EMA: Ozempic). Taken alongside insulin or sulfonylureas, it raises the risk of hypoglycaemia. The full list of contraindications, warnings and interactions is in the summary of product characteristics, published in English as part of the EPAR product information for Ozempic. Whether treatment is suitable is always a doctor's decision, weighing benefits and risks for the individual patient.
Practical points for foreigners living in Czechia
Two details catch people out. A Czech eRecept can be issued even without a Czech insurance number: a medicine that is not reimbursed can be prescribed without an insurance number and insurer code (ePreskripce FAQ on prescribing without an insurance number, in Czech). Foreigners without permanent or long-term residence are also never matched against the Register of Inhabitants, so the record stays unidentified – which blocks neither issuing nor dispensing, and only means the prescription will not show in your shared medication record (ePreskripce, in Czech). So bring the eRecept identifier itself to the counter, whether as a printed slip or sent to you by SMS or e-mail (ePreskripce, in Czech). And cross-border acceptance of foreign e-prescriptions here is only partial, as just a subset of pharmacies participates (ePreskripce, in Czech) – which is why a natively issued Czech prescription is more reliable for residents. See our guide to the Czech eRecept and, if you arrive mid-treatment, continuing GLP-1 treatment after moving to Czechia.
Frequently asked questions
Is Ozempic prescribed for weight loss in Prague?
No. Ozempic is authorised only for type 2 diabetes and is not meant to be prescribed for weight loss. The eRecept system also still requires a recorded diagnosis of type 1 or type 2 diabetes on prescriptions for the 0.25 mg and 1 mg packs (ePreskripce, 5 November 2025, in Czech). Obesity is treated with products carrying a weight-management indication, and only if a doctor judges treatment appropriate.
Is Ozempic available over the counter in the Czech Republic?
No. It is prescription-only and can be dispensed legally only at a pharmacy. Offers to sell it without a prescription, or to post it to your address, are illegal in Czechia and are associated with counterfeits, which have contained the wrong active substance entirely.
Does Czech public insurance cover weight-loss medication for foreigners?
Public insurance covers what it covers for everyone equally, and as of August 2026 medicines used for weight management are not publicly reimbursed in Czechia for obesity. The Ministry of Health says targeted reimbursement for defined patient groups is at an initial discussion stage, with blanket coverage of obesity treatment called unrealistic on cost grounds (finance.cz, May 2026, in Czech). That means self-payment for Czechs and foreigners alike, with no separate foreigner price. Details are in Czech health insurance and weight-loss medication.
Do I need a Czech GP before I can be assessed?
No. Of the 554,000 people in Czechia without a registered GP, 65% are foreign nationals – roughly 360,000 people (expats.cz), and an assessment for obesity treatment needs no referral from one. A licensed Czech doctor takes your history, decides whether treatment is appropriate, and may also decide that it is not.